杭州浙大迪迅生物基因工程有限公司Release date：2019-09-23
JACI
https://doi.org/10.1016/j.jaci.2019.02.029
Background: There have been few studies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata.
Objectives: We sought to evaluate the efficacy and safety of subcutaneous immunotherapy with 2 different doses of Alt a 1 in patients with rhinoconjunctivitis caused by sensitization to A alternata.
Method: We performed a multicenter, randomized, double- blind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctivitis with or without controlled asthma aged 12 to 65 years. Three groups were included: the placebo group and active groups receiving
0.2 or 0.37 mg of Alt a 1 per dose. The main end point was the combined symptom and medication score. Secondary end points were cutaneous reactivity and serum IgE and IgG4 levels to Alt a 1. Recorded adverse reactions were graded according to World Allergy Organization criteria.
Results: There were significant reductions in the combined symptom and medication score for the 0.37-mg dose of Alt a 1 compared with placebo at 12 months of treatment. Reduced cutaneous reactivity and IgE levels, together with increased IgG4 levels, were demonstrated for the 2 active groups versus the placebo group. A similar safety profile was found for both active groups compared with the placebo group. No serious adverse drug reactions were reported.
Conclusion: Immunotherapy with Alt a 1 was efficacious and safe, reducing the symptoms and medication consumption associated with rhinoconjunctivitis after only 1 year of treatment. The clinical benefits were associated with reduced skin reactivity and specific IgE levels and increased IgG4 levels. (J Allergy Clin Immunol 2019;144:216-23.)
All Author:
Ana Isabel Tabar, MD, PhD, Luis Prieto, MD, PhD, Pilar Alba, MD,Antonio Nieto, MD, PhD,Mercedes Rodr'?guez, MD,
Miguel Torrecillas, MD,Beatriz Huertas, MD,Elisa Go'mez, MD, PhD, Francisco Javier Ferna'ndez, MD, PhD
Miguel Blanca, MD, PhD, David Rodr'?guez, PhD, and Ricardo Palacios, PhD
Pamplona, Valencia, Madrid, Albacete, Ciudad Real, Alicante, and Malaga, Spain
[IF:13.1]
Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1https://doi.org/10.1016/j.jaci.2019.02.029
Background: There have been few studies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata.
Objectives: We sought to evaluate the efficacy and safety of subcutaneous immunotherapy with 2 different doses of Alt a 1 in patients with rhinoconjunctivitis caused by sensitization to A alternata.
Method: We performed a multicenter, randomized, double- blind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctivitis with or without controlled asthma aged 12 to 65 years. Three groups were included: the placebo group and active groups receiving
0.2 or 0.37 mg of Alt a 1 per dose. The main end point was the combined symptom and medication score. Secondary end points were cutaneous reactivity and serum IgE and IgG4 levels to Alt a 1. Recorded adverse reactions were graded according to World Allergy Organization criteria.
Results: There were significant reductions in the combined symptom and medication score for the 0.37-mg dose of Alt a 1 compared with placebo at 12 months of treatment. Reduced cutaneous reactivity and IgE levels, together with increased IgG4 levels, were demonstrated for the 2 active groups versus the placebo group. A similar safety profile was found for both active groups compared with the placebo group. No serious adverse drug reactions were reported.
Conclusion: Immunotherapy with Alt a 1 was efficacious and safe, reducing the symptoms and medication consumption associated with rhinoconjunctivitis after only 1 year of treatment. The clinical benefits were associated with reduced skin reactivity and specific IgE levels and increased IgG4 levels. (J Allergy Clin Immunol 2019;144:216-23.)
All Author:
Ana Isabel Tabar, MD, PhD, Luis Prieto, MD, PhD, Pilar Alba, MD,Antonio Nieto, MD, PhD,Mercedes Rodr'?guez, MD,
Miguel Torrecillas, MD,Beatriz Huertas, MD,Elisa Go'mez, MD, PhD, Francisco Javier Ferna'ndez, MD, PhD
Miguel Blanca, MD, PhD, David Rodr'?guez, PhD, and Ricardo Palacios, PhD
Pamplona, Valencia, Madrid, Albacete, Ciudad Real, Alicante, and Malaga, Spain
2019-9-3 Article
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP備14005341號 （浙）-非經營性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:baochunhua.cn
COPYRIGHT©2003-2024 baochunhua.cn CORPORATION. ALL RIGHTS RESERVED
Official WeChat